Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company focused on chronic low back pain, announced that its compensation committee granted an inducement stock option to Daniel Keefe, the company's recently-hired Commercial Director, Western U.S. The option to purchase 17,000 shares of common stock was granted on May 5, 2026, as a material inducement for Keefe to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of $3.20 per share, equal to Aclarion's closing stock price on the grant date. Vesting begins with one-fourth of the options vesting on the one-year anniversary of the vesting commencement date, with the remainder vesting in equal monthly installments over the subsequent three years, contingent upon Keefe's continued service. The option carries a 10-year term and is subject to an inducement stock option agreement.
This grant underscores Aclarion's strategic expansion of its commercial team, particularly in the Western U.S., as demand for its Nociscan platform accelerates. Nociscan is a SaaS platform that uses magnetic resonance spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms to noninvasively help physicians differentiate painful from nonpainful lumbar discs. The company reports triple-digit growth in utilization, supporting the need for an expanded sales force.
Aclarion's Nociscan platform addresses the chronic low back pain market by providing critical insights into pain location. Through a cloud connection, Nociscan receives MRS data from MRI machines, extracts and quantifies chemical biomarkers associated with disc pain, and uses proprietary algorithms to indicate whether a disc may be a source of pain. This information, combined with other diagnostic tools, helps physicians optimize treatment strategies.
For more information, visit www.aclarion.com. The latest news and updates relating to $ACON are available in the company’s newsroom at https://tinyurl.com/aconnewsroom.
This press release contains forward-looking statements, including those regarding increasing demand for Nociscan. These statements are subject to risks and uncertainties discussed in Aclarion's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2025. The company undertakes no obligation to update forward-looking statements.
